Home > Haematology > EHA 2022 > No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics

No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics

Presented By
Prof. Nigel Russell, Guy's and St Thomas' NHS Foundation Trust, UK
Conference
EHA 2022
Trial
Phase 3, AML19
CPX-351 does not improve response, overall survival, or event-free survival compared with FLAG-Ida in patients with acute myeloid leukaemia (AML) with adverse cytogenetics but is associated with an improvement in duration of remission and relapse-free survival, results from the AML19 trial demonstrate. AML patients with adverse cytogenetics have a poor prognosis: less than 10% will survive for 5 years or more following standard intensive chemotherapy [1]. Previous studies reported improved survival with FLAG-Ida (fludarabine/cytosine arabinoside, granulocyte-colony stimulating factor, and idarubicin) treatment in younger patients identified with high-risk AML following induction therapy and in patients with secondary AML [2]. On the other hand, CPX-351 (liposomal daunorubicin and cytarabine) has demonstrated an improved survival predominantly in older patients (>60 years) with secondary AML compared with standard chemotherapy [3]. To compare the ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on